CLINICAL PHARMACOLOGY OF HYPOLIPIDEMIC DRUGS
Keywords:
Hypolipidemic drugs, statins, PCSK9 inhibitors, LDL-C reduction, cardiovascular prevention, lipid metabolism, clinical pharmacology.Abstract
This article explores the clinical pharmacology of hypolipidemic (lipid
lowering) drugs, which play a pivotal role in the prevention and treatment of atherosclerotic
cardiovascular disease. It outlines the pharmacodynamics, pharmacokinetics, classification,
indications, and safety profiles of major hypolipidemic agents, including statins, fibrates,
bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and emerging
therapies. The article highlights their mechanisms of action, therapeutic applications, and
considerations for personalized lipid management.
References
Grundy, S. M., et al. 2018 AHA/ACC Multisociety Guideline on the Management of
Blood Cholesterol. – J Am Coll Cardiol. – 2019. – Vol. 73, №24. – P. e285–e350.
Mach, F., et al. ESC/EAS Guidelines for the management of dyslipidaemias: 2019. – Eur
Heart J. – 2020. – Vol. 41, №1. – P. 111–188.
Ridker, P. M., et al. Rosuvastatin to prevent vascular events in men and women with
elevated C-reactive protein. – N Engl J Med. – 2008. – Vol. 359, №21. – P. 2195–2207.
Sabatine, M. S., et al. Evolocumab and Clinical Outcomes in Patients with
Cardiovascular Disease. – N Engl J Med. – 2017. – Vol. 376, №18. – P. 1713–1722.
Ballantyne, C. M., et al. Efficacy and safety of bempedoic acid added to maximally
tolerated statins in patients with hypercholesterolemia. – JAMA. – 2020. – Vol. 324, №8. – P. 747–756.
